nejm semaglutide heart failure SELECT Trial

Among patients with obesity-related heart failure with preserved ejection fraction & type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations & body weight than placebo at 1 year. Full STEP-HFpEF

21.70

★★★★☆4.8 (126)

nejm Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential

23.98

★★★★★4.9 (98)

In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8

24.73

★★★★★5.0 (157)

💉 In a large real-world study, tirzepatide was associated with a lower incidence of major cardiovascular outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart

25.25

★★★★★4.7 (84)

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

27.31

★★★★★4.9 (203)

Patients with heart failure with preserved ejection fraction often have #obesity, a condition that is associated with a greater burden of heart failure–related symptoms, worse functional capacity, and more impaired quality of

20.21

★★★★★5.0 (176)

Despite the long-time use of cardiac glycosides in the treatment of heart failure, evidence of their potential benefit in patients with heart failure and reduced ejection fraction is limited. In a decades-old

21.12

★★★★★4.8 (132)